(Q48035058)

English

Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development

scientific article published on 10 August 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

Plasmodium falciparum

0 references

author name string

Don Yuen

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

Wai-Hang Leung

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

Randy Cheung

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

Caryn Hashimoto

4

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

Sui Fung Ng

5

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

Walter Ho

6

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

George Hui

7

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

language of work or name

0 references

publication date

10 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

25

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

490-499

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Processing of thePlasmodium falciparum major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Malaria parasites and erythrocyte invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

The 3' portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Precursor to the major merozoite surface antigen of Plasmodium yoelii: cloning and sequencing of the middle 1.9-kb region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Optimization of Inclusion Body Solubilization and Renaturation of Recombinant Human Growth Hormone from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Synchronization of Plasmodium falciparum Erythrocytic Stages in Culture

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Serum from Pf195 protected Aotus monkeys inhibit Plasmodium falciparum growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

based on heuristic

inferred from DOI database lookup

A malaria merozoite surface protein (MSP1)-structure, processing and function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.053

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.07.053

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16949181

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48035058&oldid=2182462284"